Lymphovascular space involvement is the sole independent predictor of lymph node metastasis in clinical early stage endometrial cancer
- 14 June 2013
- journal article
- research article
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 288 (6) , 1391-1397
Abstract
Purpose To determine clinicopathological risk factors associated with lymph node metastasis in endometrial cancer (EC). Methods Clinicopathological data of patients who underwent comprehensive surgical staging for clinical early stage EC between 2001 and 2010 at Hacettepe University Hospital was retrospectively reviewed. Results Two hundred and sixty-one patients were included. There were 26 patients (10.0 %) with lymph node metastasis. Of these, 14 (5.4 %) had pelvic lymph node metastasis, 8 (3.1 %) had both pelvic and paraaortic lymph node metastasis, and 4 (1.5 %) had isolated paraaortic metastasis. Univariate analysis revealed tumor size >2 cm, type II cancer, grade III histology, cervical stromal invasion, deep myometrial invasion, positive peritoneal cytology, adnexal involvement, serosal involvement, and presence of lymphovascular space involvement (LVSI) as significant clinicopathological factors associated with retroperitoneal lymph node metastasis. For paraaortic metastasis either isolated or with pelvic lymph node metastasis, significant factors were grade III disease, cervical stromal invasion, deep myometrial invasion, positive peritoneal cytology, adnexal involvement, serosal involvement, pelvic lymph node metastasis, and presence of LVSI. The only factor associated with isolated paraaortic lymph node metastasis was LVSI. Multivariate analysis revealed LVSI as the only independent factor for both retroperitoneal and paraaortic lymph node metastasis (odds ratio 14.9; 95 % confidence interval 3.8–59.0; p < 0.001, and odds ratio 20.9; 95 % confidence interval 1.9–69.9; p = 0.013, respectively). Conclusion Lymphovascular space involvement is the sole predictor of lymph node metastasis in EC. Therefore, LVSI status should be requested from the pathologist during frozen examination whenever possible to consider when a decision to perform or omit lymphadenectomy is made.Keywords
This publication has 28 references indexed in Scilit:
- Prospective assessment of survival, morbidity, and cost associated with lymphadenectomy in low-risk endometrial cancerGynecologic Oncology, 2012
- Is it possible to predict para-aortic lymph node metastasis in endometrial cancer?European Journal of Obstetrics & Gynecology and Reproductive Biology, 2011
- The Role of Lymphadenectomy in Endometrial CancerClinical Obstetrics and Gynecology, 2011
- Non-invasive modalities for predicting lymph node spread in early stage endometrial cancer?Surgical Oncology, 2011
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008International Journal of Cancer, 2010
- The Risk of Lymph Node Metastasis Based on Myometrial Invasion and Tumor Grade in Endometrioid Uterine Cancers: A Multicenter, Retrospective Korean StudyAnnals of Surgical Oncology, 2009
- Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised studyThe Lancet, 2009
- Systematic Pelvic Lymphadenectomy vs No Lymphadenectomy in Early-Stage Endometrial Carcinoma: Randomized Clinical TrialJNCI: Journal of the National Cancer Institute, 2008
- Predictability of retroperitoneal lymph node metastasis by using clinicopathologic variables in surgically staged endometrial cancerInternational Journal of Gynecological Cancer, 2006
- Computed tomography in endometrial carcinomaObstetrics & Gynecology, 2000